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Abstract
Multiple myeloma (MM) is a malignancy with exces-
sive production of monoclonal proteins. At disease
presentation 30% of MM patients have significant re-
nal impairment which may progress to renal failure re-
quiring dialysis. Besides chemotherapy extracorporeal
elimination procedures such as plasma exchange have
been applied as adjuvant strategies to eliminate free
light chains from circulating blood, however the effi-
cacy was poor with older techniques. We report about
a highly efficient method to eliminate serum free light
chain (sFLC) using a newly designed protein leaking
membrane in patients suffering from sFLC induced
acute renal failure. The protein leaking membrane
(HCO 1100) is characterized by increased pore size fa-
cilitating elimination of middle molecules such as
sFLC kappa (22.5 kD). The HCO 1100 membrane was
applied in a hemodialysis and hemodiafiltration mode
and compared to standard procedures (high flux he-
modialysis, hemodiafiltration and plasma exchange).
Hemodiafiltration with the protein leaking membrane
HCO 1100 was superior to all other extracorporeal re-
placement strategies in eliminating sFLC-kappa from
circulating blood. A median blood reduction rate of
40.8% (range 13.9% - 66.4%) was achieved during he-
modiafiltration. The corresponding peak clearance
rate was 25 ml/min. Importantly, the poorest elimina-
tion rate was achieved by plasma exchange followed by
standard high flux hemodialysis. Extracorporeal elimi-
nation strategies with the protein leaking membrane
HCO 1100 may be a promising adjuvant treatment
strategy for patients with sFLC nephropathy requiring
dialysis. Hemodiafiltration and to lesser extend also
hemodialysis with the HCO 1100 hemofilter are able
to eliminate substantial amounts of sFLC kappa in
MM patients.
Key words: Serum free light chains, multiple myeloma,
acute renal failure, hemodialysis, hemofiltration,
plasmapheresis.
INTRODUCTION
Multiple myeloma (MM) is a B-cell neoplasia which is
characterized by an malignant proliferation of aber-
rant plasma cells in the bone marrow. Renal impair-
ment and bone resorption are among the most impor-
tant consequences of this disease [1-3]. Novel treat-
ment options are urgently needed and are being devel-
oped [4-6]. In MM malignant plasma cells usually pro-
duce excessive amounts of monoclonal proteins,
which may involve intact immunoglobulins or serum
free light chains (sFLC) or both. In a study of 1027
patients with newly diagnosed MM, Kyle et al. report-
ed that serum creatinine level was increased in almost
half of the patients [7]. sFLC play a crucial role in
MM induced renal damage and are probably the most
important cause of renal failure in these patients. In
healthy individuals production of sFLC is approxi-
mately 500 mg/day. This “physiologic” amount of
sFLC gets rapidly cleared and degraded by the kidneys.
However, sFLC production in MM can reach 30g/day
exceeding the clearance capacity of the kidneys. Major
cause of renal failure in MM is cast nephropathy.
sFLC are normally transported to the interstitium of
the kidney via specific receptors in the proximal
tubule. Overload of these receptors by excessive
amounts of sFLC results in an overflow of them to
the distal tubule. sFLC entering the distal tubule usual-
ly bind to uromucoid (Tamm-Horsfall protein) and
form casts, which obstruct tubular fluid flow, leading
to disruption of the basement membrane and intersti-
tial damage [8-12].
The amount of sFLC necessary to cause renal im-
pairment has recently been studied by Nowrouisan et
al. [13]. The median serum concentration associated
with overflow proteinuria and hence tubular damage
were 113 mg/l for kappa and 278 mg/l for lambda
light chain, respectively. Thus, this level corresponds
to a daily production of light chains about 5 g.
Reduction of sFLC levels therefore represents a po-
tential strategy to improve renal function in acute re-
nal failure in MM. In this regard prompt initiation of
an effective chemotherapy protocol is a precondition
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tions are increasingly discussed in this regard. Studies
were initiated to investigate the use of plasma ex-
change in patients with MM and acute renal failure but
failed to show any significant benefit on renal function
[14,15].
In the present manuscript we report on a new type
of renal replacement therapy (RRT), namely RRT us-
ing a protein leaking membrane. Protein leaking mem-
branes are characterized by an increased pore size of
the dialyzer membrane promoting the elimination of
middle sized molecules such as sFLC. These mem-
branes were initially developed to improve the clear-
ance capacity for inflammatory mediators in critically
ill septic patients. Particularly one hemofilter, the
HCO1100 has been extensively studied in the regard
[16,17]. In this paper we analyzed the efficacy of the
protein leaking membrane HCO1100 to eliminate
sFLC in kappa light chain MM patients with acute re-
nal failure necessitating RRT. The elimination capacity
of the HCO1100 was studied in the hemodialysis and
hemodiafiltration mode and was compared to standard
hemodialysis procedures as well as to plasma ex-
change.
PATIENTS AND METHODS
Four consecutive patients with kappa light chain MM
were included in this study. All patients necessitated
RRT due to acute renal failure. Indication for renal re-
placement was based on clinical and laboratory
grounds. Baseline laboratory evaluation included
blood creatinine, estimated creatinine clearance
(MDRD formula), urea, acid base and electrolyte
household.
Before and after each renal replacement session
sFLC levels were measured using latex-enhanced
nephelometric immunoassays (The Binding Site,
Schwetzingen, Germany) adapted to the BN Prospec
Nephelometer (Dade-Behring, Eschborn, Germany).
The interassay coefficients of variation were 5.1% at
14.3 mg/l for the sFLC kappa and 3.6% at 28.1 mg/l
for the sFLC lambda assay with control sera (n = 10)
provided by The Binding Site.
Hemodialysis and hemodiafiltration procedures
were performed with a dialysis device allowing the
online preparation of ultrapure hemofiltration re-
placement fluids if required (AK200S, Gambro Dia-
lysatoren GmbH, Hechingen, Germany). Polyamide
high flux hemofilter (Polyflux 140H, Polyflux 210H,
steam sterilized, Gambro Dialysatoren GmbH,
Hechingen, Germany) were used for standard hemo-
dialysis. For standard hemodiafiltration the Polyflux
210H was used. Membrane specifications for the high
flux hemofilter Polyflux 140H (PF 140H) and Polyflux
210H (PF 210H) are as follows: effective surface area
1.4 qm for PF 140H and 2.1 qm for PF 210H, wall
thickness 50 ﾵm, inner diameter 215 ﾵm, membrane
pore size ~ 5nm, ultrafiltration coefficient 60 (ml/h,
mmHg) for PF 140H and 85 (ml/h, mmHg) for PF
210H, cut off point 30-40 kD, sieving coefficient for
vitamin B12 (molecular weight 1.35 kD) and inulin
(molecular weight 5.20 kD) 1.0, for ￟2 microglobulin
(molecular weight 11.8 kD) 0.7.
For RRT (either hemodialysis or hemodiafiltration)
with the protein leaking membrane a newly designed
high cut off hemofilter, the polyamide HCO 1100 he-
mofilter (HCO 1100, effective surface area 1.1 qm,
steam sterilized, Gambro Corporate Research, Hechin-
gen, Germany) was used. The high cut off hemofilter
is characterized by an increased pore diameter of ~10
nm with a membrane thickness of 50 ﾵm and an inter-
nal diameter of 215 ﾵm. The in vivo cut off point of
the membrane is approximately 60-80 kD. The he-
mofilter has been designed to increase the in-vivo per-
meability for substances in the molecular weight range
up to 60 kD. Basic features of this new hemofilter
have been recently described [18-21].
Whenever the protein leaking membrane was ap-
plied regular controls of plasma albumin and total
protein were performed (pre- and post dialysis). In
case of high transmembrane protein losses a balanced
substitution of human albumin was done. For all renal
replacement therapies blood flow rate was uniformly
set at 200 ml/h, dialysate flow rate was 500ml/min.
Dialysis time varied between 4 to 6 hours. The ultrafil-
tration rate was based on the individual fluid balance
of the patients.
In a subgroup of patients sFLC kappa - clearances
in the initial phase (10 min after start of treatment)
and at the end of therapy were calculated as follows:
clearance (ml/min) = dialysate concentration of FLC
/ inlet serum concentration of FLC x dialysate flow
rate.
A roller blood pump device was used for plasma ex-
change (BSM 22, Gambro Hospal Germany). A stan-
dard plasmafilter (Gambro PF 2000N, Gambro, Lund,
Sweden) was chosen. 2500 ml of fresh frozen plasma
were given in exchange during a 2.5 h session. Blood
flow rate was set at 100 ml/min.
STATISTICS
Data were analyzed by non-parametric tests. Paired
data were compared using the Wilcoxon rank sum test,
unpaired data by the Mann-Whitney-U-test. Results
were expressed as median and range. A p-value below
0.05 was considered significant. The statistical pro-
gram SPSS 12 (SPSS Inc., Chicago, Illinois) was used
for analysis.
RESULTS
PATIENTS CHARACTERISTICS
Patient 1 was a 73-year-old male who had previously
received 6 cycles of chemotherapy with melphalan
and prednisolone. At the time of admission he had
acute renal failure with a creatinine level of 11.3
mg/dl (eGFR 5 ml/min). Baseline sFLC kappa were
2910 mg/l. Chemotherapy with adriamycin and dex-
amethasone was initiated. In order to reduce the
amount of sFLC two treatment sessions of plasma
exchange were performed (Fig. 1). For uremia control
RRT had to be started. Six sessions of high flux he-
modialysis (Fig. 2) with a median ultrafiltration rate
of 1680 ml (range 900-2600 ml) per session were ap-
plied.
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oped MM induced acute renal failure with a creatinine
of 3.4 mg/dl and an estimated GFR of 14 ml/min at
hospital admission. sFLC kappa were 3240 mg/l.
Chemotherapy was started with adriamycin and dex-
amethasone. The patient was treated with hemodialy-
sis thrice weekly using a standard high flux hemofilter
as well as the protein leaking membrane on day 15, 18
and 25 (Fig. 3). Dialysis time was 5 hours per session.
The median ultrafiltration rate was 700 ml (range 600-
1600 ml).
Patient 3 was a 61-year-old woman with a long
known history of light chain MM disease. Previously,
this patient had been treated with various chemothera-
py protocols, including high-dose chemotherapy with
autologous stem cell transplantation, thalidomide and
dexamethasone, bortezomib, lenalidomide and dexam-
ethasone. She was admitted to the hospital due to MM
induced acute renal failure. At admission creatinine
was 5.4 mg/dl (eGFR 9 ml/min). Baseline sFLC kap-
pa were 13,300 mg/l. Treatment was started with three
sessions of hemodialysis using the protein leaking
membrane (Fig. 4). Median ultrafiltration was 3300 ml
(range 2200-4000 ml). After the third hemodialysis
session chemotherapy with adriamycin and dexam-
ethasone was started. The hemodialysis procedures
were followed by 5 sessions of hemodiafiltration using
the same hemofilter (Fig. 5). Median ultrafiltration was
2950 ml (2650 – 4600 ml). After hemodiafiltration 4
sessions of standard hemodialysis using a standard he-
mofilter (PF 140H, Gambro) were performed (Fig. 4).
Median ultrafiltration was 400 ml (300 – 1000 ml).
Although chemotherapy was promptly initiated, the
patient developed progressive disease with an increase
of sFLC kappa from 5740mg/l at admission to 6640
mg/l after the first cycle of chemotherapy. Thus,
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Fig. 1. Reduction rate (%) of sFLC kappa during two ses-
sions of plasma exchange. Treatment time was 2.5 hour per
session (Patient 1).
Fig. 3. Reduction rate (%) of sFLC kappa with hemodialysis
using the protein leaking membrane HCO1100. Treatment
time is shown in hours (Patient 2).
Fig. 2. Reduction rate (%) of sFLC kappa with he-
modialysis using the high flux membrane PF 140H.
Treatment time is shown in hours (Patient 1).
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amethasone. Contemporaneously hemodialysis apply-
ing a standard high flux hemofilter (Fig. 4) was per-
formed. A detailed sequence of the hemofilters used
in this patient is given in Figures 4 and 5.
Patient 4 was a 51 year old woman. This previously
untreated patient was admitted to our hospital due to
hypercalcaemia of 3.7 mmol/l and acute renal failure
with a creatinine of 5.3 mg/dl (eGFR 12 ml/min).
Serum FLC kappa was 15,100 mg/l at presentation.
Hemodialysis using the protein leaking hemofilter was
immediately started. A total of 9 hemodialysis sessions
with a median ultrafiltration rate of 415 ml (range 0-
1500 ml) were performed. Simultaneously chemothera-
py with adriamycin and dexamethasone was initiated
(Fig. 6). Furthermore the patient received 7 sessions of
hemodiafiltration (HC1100) with a median ultrafiltra-
tion of 550 ml (range 0-1500 ml) (Fig. 7). However,
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Fig.4. Reduction rate (%) of sFLC kappa by hemodialysis. Treatment time is shown in hours (Patient 3).
Fig. 5. Reduction rate (%) of sFLC kappa with hemodiafiltration applying the HCO 1100 and PF210H hemofilter. Treatment
time is shown in hours (Patient 3).
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uncontrolled and progressive disease. Thus, chemother-
apy was switched to bortezomib and dexamethasone.
SFLC REDUCTION RATES AND CLEARANCE
Our data reveal that hemodiafiltration with the protein
leaking membrane HCO 1100 was superior to all other
extracorporeal replacement strategies in eliminating
sFLC from circulating blood (Fig. 8). With the protein
leaking membrane HCO 1100 a median reduction rate
of 40.8% (range 13.9% - 66.4%) was achieved during
hemodiafiltration and 23.7% (range –32.9% - 55.8%)
during hemodialysis (p = 0.017) (Fig. 8). Eliminating
the extremes (there were two protein leaking mem-
brane hemodialysis sessions were the sFLC increased
during dialysis, probably due to an highly active dis-
ease) significance still remained in favor for the he-
modiafiltration mode (p=0.04). Of interest, lowest
sFLC kappa elimination rates were achieved with plas-
ma exchange. The percentage decline of sFLC kappa
during plasma exchange was only 14.5% and 9.9 %, re-
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Fig. 6. Elimination of sFLC kappa with hemodialysis using protein leaking filter. Treatment time is shown in hours (Patient 4).
Fig. 7. Elimination of sFLC kappa using
hemodiafiltration with protein leaking he-
mofilter HCO 1100. Treatment time is
shown in hours (Patient 4).
Fig. 8. Box-Whiskers-Plot: Summary of median sFLC kappa
reduction rates by different renal replacement strategies.
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modialysis achieved a median reduction rate of 21.4%
(range -7.4% - 32.7%, Fig. 2).
The median overall reduction rate for conventional
high flux hemodialysis was 21.2 % (range -7,5% -
41.5%). Comparing the small (PF 140H) versus the
large surface area membrane (PF 210H) revealed a
slight, but statistically not significant advantage in fa-
vor for the large surface area membrane (p=0.66).
Nevertheless, a significant difference was found be-
tween standard high flux hemodiafiltration (PF 210H)
and hemodialysis (PF 210H), in favor for the hemodi-
afiltration mode (p=0.005) (Fig. 8).
In parallel best clearance rates were achieved during
hemodiafiltration with the protein leaking membrane
followed by hemodialysis with the protein leaking
membrane. Maximum clearances were achieved in the
initial phase of the treatment with values reaching up
to 25 ml/min during HCO 1100 compared to 5
ml/min during conventional therapy (PF 210H). How-
ever, even when the protein leaking membrane was
used clearance rates declined to around 10 ml/min at
4 hours.
SAFETY CRITERIA
Treatments with the protein leaking membrane HCO
1100 were well tolerated hemodynamically. Blood
pressure drops were equally distributed between stan-
dard high flux treatments and treatments performed
with the protein leaking membrane.
Median albumin values before and after treatment
with the protein leaking membrane were 3.3 (range
3.1-3.7) and 3.4 (range 3.3-3.89), respectively. Values
did not differ to those obtained during standard high
flux hemodialysis or hemodiafiltration. Albumin sub-
stitution was not necessary.
DISCUSSION
In this study we analyzed different modes of extracor-
poreal elimination techniques for reducing sFLC kap-
pa in patients with kappa light chain MM associated
nephropathy requiring dialysis. We compared a novel
type of hemofilter, a so-called protein leaking mem-
brane, applied in a hemodialysis and hemodiafiltration
mode to standard procedures such as high flux he-
modialysis and hemodiafiltration as well as plasma ex-
change.
We found a superiority in favor for the protein leak-
ing membrane particularly when applied in the he-
modiafiltration mode. Plasma exchange achieved the
lowest effects on sFLC. High flux hemofilters, particu-
larly high flux membranes with a large surface area
reached surprisingly good reduction rates for sFLC
kappa. However, when the clearance rates were ana-
lyzed, a significant advantage in favor for the protein
leaking membrane was found. Up to 10 fold higher
clearance rates were achieved with the protein leaking
membrane compared to the high flux hemofilter (PF
210H).
Kappa light chains have a molecular weight of
around 22.5 kD. They are normally cleared in 2-4
hours at 40% of the glomerular filtration rate. Howev-
er, removal may be significantly prolonged in patients
with renal failure and can reach up to 2-3 days in MM
patients in complete renal failure [22,23]. Free light
chains are distributed in similar concentrations in
serum, extra-vascular compartment and in tissue ede-
ma fluid [24]. The intra-vascular compartment proba-
bly contains only 15-20% of the total amount. Thus,
redistribution from the interstitium into the vascular
compartment occurs which makes a long extracorpo-
real treatment session necessary for an effective re-
moval of sFLC. Clark et al. studied the effects of plas-
ma exchange on clinical course of MM patients [15].
They performed 5 to 7 plasma exchanges in their pa-
tients and found that it did not reduce a composite
outcome of death, dialysis dependence, or glomerular
filtration rate at 6 months. However, they initiated the
study before the routine availability of the im-
munoglobulin free light chain assay, thus sFLC were
not investigated and subgroup analyses for light chain
diseases could not be performed. Very recently, Cserti
and co-workers studied sFLC concentration in two pa-
tients and found that plasma exchange failed to effec-
tively lower sFLC levels [25]. Plasma exchange was
performed using a continuous-flow cell separator. In
our study plasma exchange was studied in one patient.
The median reduction rate for sFLC kappa was only
12,3%. The plasma exchange volume was 2.5 L, which
is a standard dose for plasma exchange. Based on this
finding and having in mind the results from Clark and
co-workers we decided not to proceed with plasma ex-
change in light chain MM since the low serum reduc-
tion rates do not compensate for the potential risks
(allergic reaction, infections etc) [15].
Hemodialysis with newly designed protein leaking
membranes may represent an alternative strategy to
clear sFLC more effectively. Due to an increased pore
size of these membranes the elimination of middle
sized molecules including sFLC is eased. Very recently
Hutchison and co-workers studied the impact of dif-
ferent protein leaking membranes on the capacity to
clear sFLC [26]. Hemodialysis was treatment modality
in all patients. Best results were achieved with the
Gambro HC 1100 membrane. Excellent clearance
rates for both kappa and lambda light chains were re-
ported which translated in a significant removal of
sFLC in light chain MM patients with acute renal fail-
ure. Serum-FLC could be reduced by 35 to 70%.
In the present study, we analyzed the Gambro HCO
1100 membrane in the hemodialysis and hemodiafil-
tration mode extending the results of Hutchison and
co-workers. We found that the hemodiafiltration mode
had an advantage over the hemodialysis mode. The
maximum reduction rate for sFLC kappa was 66%
which is line with the data reported by Hutchison.
Interestingly, we observed a high variability in the
inter- and intra-patient reduction rate for sFLC kappa
during HCO 1100 RRT which is best explained by a
variable activity status of the underlying disease. While
patient 2 and 4 had a more or less constant sFLC kap-
pa reduction rate of around 25 to 30% over time (indi-
cating a stable disease activity), patient 3 showed an in-
crease in sFLC kappa on day 1 of the first cycle of
chemotherapy with adriamycin and dexamethasone
from 4320 mg/l before starting HCO 1100 dialysis to
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increased even further in the dialysis free interval and
reached 9739mg/l on the consecutive dialysis day (pre-
dialysis value). The missing fall in sFLC kappa can be
clearly interpreted as a sign of rapid disease progres-
sion. A switch in chemotherapy to bortezomib was
done which resulted in a prompt decline in sFLC kap-
pa. A highly effective chemotherapy is a precondition
for treating MM associated nephropathy and must be
initiated simultaneously to the RRT. A further example
for this is patient 4. After the first cycle of chemother-
apy with adriamycin and dexamethasone sFLC de-
creased from 6270 mg/l (day1) to 3500 mg/l (day14),
but then increased up to 6450 mg/l (day 28) again.
Thus, we changed the regimen to bortezomib and dex-
amethasone. At day 16 after starting this chemothera-
py regime sFLC dropped to 48.8 mg/l. Here, a combi-
nation of an effective chemotherapy and hemodialysis
led to a very good result.
Importantly, the observed rebound phenomenon af-
ter RRT also results from the distribution of sFLC into
the different body compartments [24]. Only around
20% of the total amount of sFLC are found in circulat-
ing blood whereas 80% lay in the so called “third com-
partment”. Redistribution processes have to take place
before these “trapped” sFLC can be eliminated. Hence,
sustained elimination procedures are required.
RRT with some protein leaking membranes can lead
to substantial transmembrane protein losses particularly
when used on a extended daily base as propagated by
Hutchison et al. [26]. However, in our study population
a severe protein depletion was not observed.
In conclusion, extracorporeal elimination strategies
with the protein leaking membrane HCO 1100 may be
a new and promising adjuvant treatment strategy for
patients with sFLC nephropathy requiring dialysis. He-
modiafiltration and to lesser extend also hemodialysis
with the HCO 1100 hemofilter are able to eliminate
substantial amounts of sFLC kappa in MM patients.
However, a rebound phenomenon is observed which
not only demands a prolonged and repeated treatment
strategy but also an effective chemotherapy protocol
as a precondition for renal recovery.
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